Imaging with radiolabelled monoclonal antibody (MUJ591) to prostate-specific membrane antigen in staging of clinically localized prostatic carcinoma: comparison with clinical, surgical and histological staging.
BJU Int
; 95(9): 1232-6, 2005 Jun.
Article
en En
| MEDLINE
| ID: mdl-15892807
ABSTRACT
OBJECTIVE:
To evaluate the reliability of prostate scintigraphy using a radiolabelled antibody (MUJ591) raised against the external domain of prostate-specific membrane antigen (PSMA) in the staging of early prostate cancer. PATIENTS ANDMETHODS:
This was a prospective study of 16 patients who had radical retropubic prostatectomies (median PSA 9.75 ng/mL). All patients underwent PSMA imaging using MUJ591 radiolabelled with (99m)Tc using a photo-reduction technique.RESULTS:
The findings of prostate imaging and histology were identical in seven patients. Scans showed understaging and overstaging in six and three patients, respectively.CONCLUSIONS:
PSMA scintigraphy using (99m)Tc-labelled MUJ591 identifies the presence of prostate cancer, but is not sensitive in delineating micro-invasion of the capsule, seminal vesicles or bladder neck. As in other studies it seems to be useful in detecting prostate bed recurrence and distant micrometastasis.
Buscar en Google
Bases de datos:
MEDLINE
Asunto principal:
Neoplasias de la Próstata
/
Glutamato Carboxipeptidasa II
/
Anticuerpos Monoclonales
/
Estadificación de Neoplasias
/
Antígenos de Superficie
Tipo de estudio:
Evaluation_studies
/
Observational_studies
/
Prognostic_studies
Límite:
Aged
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
BJU Int
Asunto de la revista:
UROLOGIA
Año:
2005
Tipo del documento:
Article